30 closest matches · ranked by relevance
Lung Cancer
Primary: Progression-free Survival at 6 Months — 60 percentage of participants
Cancer
Primary: Evaluation of Overall Survival — 50.4 weeks
Non-Small Cell Lung Cancer
Primary: Time to Disease Progression — 4.6; 6.0; 4.1 months — p=0.40
Lung Cancer
Primary: Time to Progression (TTP), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease — 4.7…
Lung Cancer
Primary: Patient Response — 2; 1; 2; 27 participants
Non-small Cell Lung Cancer
Primary: Progression Free Survival — 9.7; 4.2 months
Non-Small-Cell Lung Carcinoma
Primary: Progression-free Survival (PFS) — 5.45; 5.22 months — p=0.848
Non-Small-Cell Lung Cancer
Primary: Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate) — 52.8; 39.3 percentage
Squamous Non-small Cell Lung Cancer
Primary: Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0 Participants
Non Small Cell Lung Cancer
Primary: Overall Survival Time (OS) — 11.5; 9.9 Months — p=0.0120
Metastatic Non-squamous Non Small Cell Lung Cancer
Primary: The Primary Efficacy Endpoint is Progression Free Survival, Analyzed in the Treated Population. PFS is Assessed From Randomization Until Either Tumor Progression, as Per…
Non-small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 9.95; 6.83 Months — p=0.0618
Non-Small Cell Lung Cancer
Primary: Survival Without Grade 3 or 4 Toxicity — 3.2; 0.7 months — p=<0.001
Squamous NSCLC
Primary: PFS(Progression Free Survival) — 5.5; 4.9 months
Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 10.9; 10.7 months — p=0.5157
Non-small Cell Lung Cancer Metastatic
Primary: Time to Disease Progression — 15 weeks
Non-Squamous Non-Small Cell Lung Cancer
Primary: Median Progression Free Survival (PFS) Time — 6.0; 7.6 months — p=<0.0001
Carcinoma, Non-Small-Cell Lung
Primary: Overall Survival (OS) in the ITT (Non-squamous) Population — 376; 379 days — p=0.401
Lung Cancer
Primary: Maximum Dose of Erlotinib When Given Together With Carboplatin, Paclitaxel, and Thoracic Conformal Radiotherapy (Phase I [Closed to Accrual as of 1/3/2008]) — 0; 0; 2 DLTs
Lung Cancer
Primary: Confirmed Response Rate (Complete Response and Partial Response) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) (Phase II Patients Only) — 19; 20…
Lung Cancer
Primary: Progression-free Survival — 12.6 months
Small Cell Lung Cancer
Primary: One-year Survival, The Percentage of Patients Who Are Alive One Year After Completing Protocol Treatment — 54 percentage of participants
Lung Cancer
Primary: Overall Response Rate — 26 Percentage of participants
Non Small Cell Lung Cancer
Primary: Overall Survival Time (OS) — 11.3; 11.5 Months — p=0.9561
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Non Small Cell Lung Cancer
Primary: Phase 2: Progression-Free Survival Time — 4.7; 1.5 months
Non-Small Cell Lung Cancer (NSCLC)
Primary: Overall Survival (OS) Time — 16.1; 15.5 months
Lung Cancer
Primary: To Establish Rate of Non-progressive Disease at 4 Months in Patients With Advanced NSCLC Who Have Been Designated PS2 by Their Treating Physician — 28 percentage of…
Lung Cancer
Primary: Maximum Tolerated Dose of Erlotinib Hydrochloride (Phase I) — 150 mg daily